Recent 8-K filings for NRXS

• April 21, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02 ◈ Earnings Releases

  Neuraxis reports preliminary Q1 2026 net sales of $1.6M, up 77% YoY; operating loss of $1.7M

  Cash and cash equivalents ~$7.1M as of March 31, 2026.

• October 24, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+

  FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.

• October 23, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02

  Neuraxis reports preliminary Q3 net sales $0.8M, operating loss $2.1M

  Preliminary unaudited cash and equivalents of $4.4M as of September 30, 2025.

• July 3, 2025, 7:59 PM ET other material materiality 0.60 negative item 1.01item 1.02item 5.02item 9.01

  Neuraxis ends Masimo partnership on NSS-2 Bridge; pays $200K, forfeits future royalties

  Terminated License and Collaboration Agreement with Masimo Corp., effective July 1, 2025.

• May 22, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Neuraxis announces $5.0M registered direct offering of 1.54M shares at $3.25/share

  Offering of 1,538,461 shares at $3.25/share; gross proceeds ~$5.0M before fees.

• January 8, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M

  Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).

• November 15, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 9.01

  Neuraxis raises ~$5M through Series B Convertible Preferred Stock to three investors

  Sold 2,100,840 shares of Series B Preferred Stock at $2.38 stated value for aggregate $5M, closed Nov 13, 2024.

• November 12, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment

  Revenue $667K, +40% YoY; unit sales +50%.

• August 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives

  Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.

• May 28, 2024, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01

  Neuraxis raises $3M via convertible notes at 8.5% interest; warrants amended

  Issued ~$3M aggregate principal convertible notes to three institutional investors; 8.5% annual interest payable quarterly.

• April 16, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change

  Neuraxis COO Dan Clarence terminated; severance through Oct 2024

  COO Dan Clarence employment terminated effective April 10, 2024.

• April 9, 2024, 7:59 PM ET other material materiality 0.80 negative item 2.02item 4.02item 9.01 ◈ Auditor Changes◈ Earnings Releases

  NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error

  FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.

• March 28, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Neuraxis increases Flagstaff financing to $5M, replaces preferred with convertible note

  Amendment raises Flagstaff investment from $3M to $5M via convertible promissory note.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

4 positive 4 negative 16 neutral

source · NRXS on sec.gov